The organization asked J&J to publicly commit that it will drop any secondary patents for its drug-resistant tuberculosis drug Sirturo (bedaquiline) in countries with a high disease burden.
Tag Archive for: Johnson & Johnson
J&J, Merck and Pfizer are the subjects of a House Judiciary Committee investigation for their alleged participation in a government-sanctioned censorship campaign during the COVID-19 pandemic.
J&J vice president of litigation Erik Haas said in a statement that the company would appeal the verdict, calling it “irreconcilable with the decades of independent scientific evaluations confirming Johnson’s Baby Powder is safe, does not contain asbestos and does not cause cancer.”
J&J’s pharmaceutical unit Janssen filed its complaint in U.S. District Court for the District of New Jersey. It broadly follows the other related lawsuits, arguing that the program is unconstitutional and amounts to “confiscation of constitutionally protected property.”
The U.S. health regulator said it had received reports of pediatric and adult patients suffering burn injuries when the tools, sold under the brand names MEGA 2000 and MEGA SOFT Reusable Patient Return Electrodes, were used on them.
Johnson & Johnson has licensed Nanobiotix’s lead radioenhancer candidate, designed to increase the efficacy of radiation treatment in cancers, capitalizing on the latter’s rocky financial situation.
Lawyers for a California man who says he developed a rare cancer from exposure to asbestos in Johnson & Johnson’s talc-based baby powder on Monday urged a jury to order the company to pay heavy punitive damages, calling its conduct negligent and “despicable.”
The announcement comes after the company struck a $1.75 billion deal with Swiss drugmaker Novartis late last month to buy several eye-care products including anti-inflammation eye drop Xiidra.
Starting on Tuesday, U.S. Bankruptcy Judge Michael Kaplan in Trenton is due to hear several days of evidence and arguments before making a ruling.
Following a May 2023 settlement with Amgen, J&J has also signed an agreement with Teva and Alvotech, allowing their Stelara biosimilar to enter the U.S. no later than February 21, 2025.